Dr Evans, a lecturer in microbiology and medical biotechnology, said: "One of the greatest threats to modern medicine is the increasing prevalence of antibiotic-resistant bacteria, and with
Acinetobacter baumannii we are essentially talking about something that is as at least as dangerous as MRSA and much more difficult to eradicate.
It's multidrug resistant
Acinetobacter baumannii and it was introduced into North America by troops returning from the Middle East in Canadian soldiers injured and requiring mechanical ventilation as a part of the medical treatment.
Background:
Acinetobacter baumannii causes infections of respiratory, urinary tract, blood stream and surgical sites.
Acinetobacter baumannii is an emerging gram-negative nosocomial pathogen responsible for an increasing number of infections, especially among intensive-care-unit patients.
The emergence of multidrug-resistant
Acinetobacter baumannii in Colombia: A time-series analysis, 2001-2007
The genomic identification of Colombian
Acinetobacter baumannii clinical isolates by RFLP-PCR analysis of the 16S-23S rRNA gene spacer region
Acinetobacter baumannii multidrug and pandrug resistant: perspective, resistance mechanisms and treatment
All isolates of
acinetobacter baumannii (n=32) were resistant to ampicillin, ceftriaxone and ceftazidime but sensitive to polymyxin B.
Acinetobacter baumannii has been considered the prevailing pathogen responsible for ventilator-associated pneumonia (VAP), a condition associated with high morbidity and mortality, among patients in Intensive Care Units (ICUs).
Acinetobacter baumannii was mostly sensitive to amikacin (65%; n = 13/20) and ceftazidime (75%; n = 15/20), with high levels of resistance to gentamicin (85%) and meropenem (80%).
Spread of Multidrug-Resistant
Acinetobacter baumannii Clone, France
Prevalence of multi drug resistant
Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan.
